Symbols / IXHL Stock $4.03 +6.33% Incannex Healthcare Inc.

Healthcare • Drug Manufacturers - Specialty & Generic • Australia • NCM
IXHL (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
CEO Mr. Joel Bradley Latham
Exch · Country NCM · Australia
Market Cap 56.31M
Enterprise Value -20.60M
Income -48.50M
Sales —
FCF (ttm) -9.41M
Book/sh 6.13
Cash/sh 5.77
Employees 12
Insider 10d —
IPO Mar 02, 2022
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -2.06
PEG —
P/S inf
P/B 0.66
P/C —
EV/EBITDA 0.81
EV/Sales —
Quick Ratio 47.96
Current Ratio 48.27
Debt/Eq 0.22
LT Debt/Eq —
EPS (ttm) -22.20
EPS next Y -1.96
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-02-13
Earnings (prior) 2026-02-13
ROA -36.96%
ROE -130.43%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 13.97M
Shs Float 10.69M
Insider Own 10.56%
Instit Own 2.89%
Short Float 6.57%
Short Ratio 1.75
Short Interest 908.02K
52W High 49.80
vs 52W High -91.91%
52W Low 2.40
vs 52W Low 67.92%
Beta 2.73
Impl. Vol. 1.69%
Rel Volume 0.95
Avg Volume 529.54K
Volume 504.33K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $3.79
Price $4.03
Change 6.33%
About

Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. Incannex Healthcare Inc. is headquartered in Sydney, Australia.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$4.03
Latest analyst target
3. DCF / Fair value
$-12.13
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.03
Low
—
High
—
Mean
—
News
RSS: Latest IXHL news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-11-14 LATHAM JOEL Chief Executive Officer — 22,608,692 $0.00 $0
2025-11-14 ANASTASSOV GEORGE Director — 1,686,956 $0.00 $0
2025-11-14 VALENTINE TROY ROBERT Director — 11,302,608 $0.00 $0
2025-11-14 SWAN JOSEPH Chief Financial Officer — 869,565 $0.00 $0
2025-11-14 SWAN JOSEPH Director — 1,686,956 $0.00 $0
2025-11-14 WIDDOWS PETER Director — 1,686,956 $0.00 $0
2024-10-23 SWAN JOSEPH Officer — 100,476 $0.00 $0
2024-05-06 SWAN JOSEPH Chief Financial Officer — 50,793 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total Revenue
0.01
0.00
0.00
-100.00%
1.43
Operating Revenue
0.01
0.00
0.00
-100.00%
1.43
Cost Of Revenue
—
0.00
-100.00%
0.00
-99.36%
0.69
Reconciled Cost Of Revenue
—
0.00
-100.00%
0.00
-99.36%
0.69
Gross Profit
—
0.00
+100.00%
-0.00
-100.59%
0.74
Operating Expense
18.62
+36.52%
13.64
+34.23%
10.16
+9.08%
9.31
Research And Development
12.88
+104.14%
6.31
+70.73%
3.70
+3.55%
3.57
Selling General And Administration
17.07
+115.43%
7.92
+13.16%
7.00
+21.29%
5.77
Selling And Marketing Expense
1.05
-15.53%
1.25
-33.89%
1.89
-42.14%
3.27
General And Administrative Expense
16.02
+139.94%
6.67
+30.53%
5.11
+103.85%
2.51
Salaries And Wages
11.74
+160.76%
4.50
+87.98%
2.39
+68.03%
1.42
Other Gand A
3.93
+88.09%
2.09
-20.89%
2.64
+165.11%
1.00
Other Operating Expenses
-11.43
-1574.08%
-0.68
—
-0.03
Total Expenses
18.62
+36.52%
13.64
+34.18%
10.16
+1.65%
10.00
Operating Income
-18.61
-36.43%
-13.64
-34.18%
-10.16
-18.55%
-8.57
Total Operating Income As Reported
-30.04
+39.52%
-49.67
—
—
EBITDA
-18.33
-35.25%
-13.55
-33.31%
-10.16
-18.55%
-8.57
Normalized EBITDA
-18.30
-183.69%
21.86
+317.09%
-10.07
—
Reconciled Depreciation
0.10
+17.05%
0.09
0.00
0.00
EBIT
-18.43
-35.13%
-13.64
-34.18%
-10.16
-18.55%
-8.57
Total Unusual Items
-0.03
+99.92%
-35.41
-38139.73%
-0.09
—
Total Unusual Items Excluding Goodwill
-0.03
+99.92%
-35.41
-38139.73%
-0.09
—
Special Income Charges
0.00
+100.00%
-35.35
-38067.39%
-0.09
0.00
Other Special Charges
—
35.35
—
—
Write Off
—
0.00
-100.00%
0.09
0.00
Net Income
-18.46
+62.18%
-48.81
-376.09%
-10.25
-19.99%
-8.54
Pretax Income
-18.43
+62.24%
-48.81
-376.09%
-10.25
-19.99%
-8.54
Net Non Operating Interest Income Expense
0.21
-14.52%
0.24
+5486.62%
0.00
+114.32%
0.00
Net Interest Income
0.21
-14.52%
0.24
+5486.62%
0.00
+114.32%
0.00
Interest Income Non Operating
0.21
-14.52%
0.24
+5486.62%
0.00
+114.32%
0.00
Interest Income
0.21
-14.52%
0.24
+5486.62%
0.00
+114.32%
0.00
Other Income Expense
-0.03
+99.92%
-35.41
-38139.73%
-0.09
-446.54%
0.03
Other Non Operating Income Expenses
—
1.38
+74.56%
0.79
+2851.07%
0.03
Gain On Sale Of Security
-0.03
+58.21%
-0.07
—
—
Tax Provision
0.03
0.00
0.00
0.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
-0.01
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-18.46
+62.18%
-48.81
-376.09%
-10.25
-19.99%
-8.54
Net Income From Continuing Operation Net Minority Interest
-18.46
+62.18%
-48.81
-376.09%
-10.25
-19.99%
-8.54
Net Income From Continuing And Discontinued Operation
-18.46
+62.18%
-48.81
-376.09%
-10.25
-19.99%
-8.54
Net Income Continuous Operations
-18.46
+62.18%
-48.81
-376.09%
-10.25
-19.99%
-8.54
Normalized Income
-18.44
-37.64%
-13.40
-31.86%
-10.16
—
Net Income Common Stockholders
-18.46
+62.18%
-48.81
-376.09%
-10.25
-19.99%
-8.54
Diluted EPS
-34.50
-3241.04%
-1.03
-0.07%
-1.03
—
Basic EPS
-34.50
-3241.04%
-1.03
-0.07%
-1.03
—
Basic Average Shares
0.54
-95.79%
12.81
+29.02%
9.93
—
Diluted Average Shares
0.54
-95.79%
12.81
+29.02%
9.93
—
Diluted NI Availto Com Stockholders
-18.46
+62.18%
-48.81
-376.09%
-10.25
-19.99%
-8.54
Depreciation Amortization Depletion Income Statement
0.10
+17.05%
0.09
0.00
—
Depreciation And Amortization In Income Statement
0.10
+17.05%
0.09
0.00
—
Depreciation Income Statement
0.10
+17.05%
0.09
0.00
—
Other Taxes
—
-0.67
-24.69%
-0.54
0.00
Rent And Landing Fees
0.35
+314.29%
0.08
+8.70%
0.08
-11.20%
0.09
Rent Expense Supplemental
0.35
+314.29%
0.08
+8.70%
0.08
-11.20%
0.09
Line Item Trend 2023-06-30 2022-06-30
Total Assets
23.78
-8.73%
26.06
Current Assets
23.00
-11.75%
26.06
Cash Cash Equivalents And Short Term Investments
22.12
-14.25%
25.80
Cash And Cash Equivalents
22.12
-14.25%
25.80
Cash Financial
22.08
-14.39%
25.80
Receivables
0.19
-12.92%
0.22
Accounts Receivable
0.29
—
Gross Accounts Receivable
—
—
Other Receivables
—
—
Taxes Receivable
0.19
-5.79%
0.20
Prepaid Assets
0.69
+1566.60%
0.04
Other Current Assets
1.04
—
Total Non Current Assets
0.79
0.00
Net PPE
0.79
0.00
Gross PPE
0.81
0.00
Accumulated Depreciation
-0.02
—
Properties
0.00
—
Buildings And Improvements
0.49
—
Machinery Furniture Equipment
0.16
—
Construction In Progress
0.16
—
Other Properties
1.19
—
Goodwill And Other Intangible Assets
34.90
0.00
Total Liabilities Net Minority Interest
2.96
+113.87%
1.38
Current Liabilities
2.55
+84.37%
1.38
Payables And Accrued Expenses
2.17
+84.15%
1.18
Payables
1.75
+95.36%
0.89
Accounts Payable
1.75
+95.36%
0.89
Other Payable
—
—
Current Accrued Expenses
0.43
+49.06%
0.29
Pensionand Other Post Retirement Benefit Plans Current
0.26
+29.87%
0.20
Current Debt And Capital Lease Obligation
0.11
—
Current Capital Lease Obligation
0.11
0.00
Current Deferred Liabilities
0.00
—
Current Deferred Revenue
0.00
—
Total Non Current Liabilities Net Minority Interest
0.41
0.00
Long Term Debt And Capital Lease Obligation
0.41
0.00
Long Term Capital Lease Obligation
0.41
0.00
Stockholders Equity
20.82
-15.60%
24.67
Common Stock Equity
20.82
-15.60%
24.67
Capital Stock
0.00
-100.00%
59.56
Common Stock
0.00
-100.00%
59.56
Preferred Stock
0.00
—
Share Issued
0.53
+22.80%
0.43
Ordinary Shares Number
0.53
+22.80%
0.43
Treasury Shares Number
0.00
0.00
Additional Paid In Capital
116.29
—
Retained Earnings
-92.21
-127.99%
-40.45
Gains Losses Not Affecting Retained Earnings
-3.25
—
Other Equity Adjustments
—
—
Total Equity Gross Minority Interest
20.82
-15.60%
24.67
Total Capitalization
20.82
-15.60%
24.67
Working Capital
20.45
-17.13%
24.67
Invested Capital
20.82
-15.60%
24.67
Total Debt
0.52
0.00
Capital Lease Obligations
0.52
0.00
Net Tangible Assets
20.82
-15.60%
24.67
Tangible Book Value
20.82
-15.60%
24.67
Foreign Currency Translation Adjustments
-3.25
—
Notes Receivable
0.07
+298.91%
0.02
Other Equity Interest
7.98
+43.68%
5.56
Line Item Trend 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Operating Cash Flow
-15.85
-47.41%
-10.75
-22.00%
-8.81
-69.70%
-5.19
Cash Flow From Continuing Operating Activities
-15.85
-47.41%
-10.75
-22.00%
-8.81
-69.70%
-5.19
Net Income From Continuing Operations
-18.46
+62.18%
-48.81
-376.09%
-10.25
-19.99%
-8.54
Depreciation Amortization Depletion
0.10
+17.05%
0.09
0.00
0.00
Depreciation And Amortization
0.10
+17.05%
0.09
0.00
0.00
Other Non Cash Items
—
-0.00
+98.96%
-0.41
-114.05%
2.91
Stock Based Compensation
8.93
+315.45%
2.15
+113.30%
1.01
+123.47%
0.45
Provisionand Write Offof Assets
—
—
0.00
+100.00%
-0.01
Operating Gains Losses
0.03
—
—
—
Net Foreign Currency Exchange Gain Loss
0.03
0.00
—
—
Change In Working Capital
-6.45
-117.99%
35.83
+4146.49%
0.84
+19387.13%
0.00
Change In Receivables
-9.84
0.00
+100.00%
-0.06
-139.33%
0.16
Change In Inventory
—
—
0.00
-100.00%
0.14
Change In Prepaid Assets
0.37
+158.95%
-0.63
—
—
Change In Payables And Accrued Expense
3.02
+173.82%
1.10
+44.44%
0.76
+449.21%
-0.22
Change In Payable
3.02
+173.82%
1.10
—
—
Change In Other Current Assets
0.00
-100.00%
35.35
+96038.66%
0.04
+28350.58%
0.00
Change In Other Current Liabilities
—
0.07
-35.57%
0.11
+239.54%
-0.08
Investing Cash Flow
-0.28
+12.34%
-0.32
0.00
-100.00%
0.02
Cash Flow From Continuing Investing Activities
-0.28
+12.34%
-0.32
0.00
-100.00%
0.02
Net PPE Purchase And Sale
-0.28
+12.34%
-0.32
0.00
0.00
Purchase Of PPE
-0.28
+12.34%
-0.32
0.00
—
Sale Of PPE
—
—
0.00
0.00
Capital Expenditure
-0.28
+12.34%
-0.32
—
—
Net Business Purchase And Sale
—
—
0.00
-100.00%
0.02
Financing Cash Flow
0.00
-100.00%
8.18
-71.15%
28.33
+204.08%
9.32
Cash Flow From Continuing Financing Activities
0.00
-100.00%
8.18
-71.15%
28.33
+204.08%
9.32
Net Issuance Payments Of Debt
—
-0.04
0.00
—
Repayment Of Debt
—
-0.04
0.00
—
Long Term Debt Payments
—
-0.04
0.00
—
Net Long Term Debt Issuance
—
-0.04
0.00
—
Net Common Stock Issuance
0.00
-100.00%
8.18
-71.15%
28.33
+204.08%
9.32
Changes In Cash
-16.12
-457.85%
-2.89
-114.80%
19.52
+370.66%
4.15
Effect Of Exchange Rate Changes
-0.14
+83.01%
-0.82
0.00
0.00
Beginning Cash Position
22.12
-14.38%
25.83
+311.62%
6.28
+131.82%
2.71
End Cash Position
5.86
-73.52%
22.12
-14.25%
25.80
+276.33%
6.85
Free Cash Flow
-16.12
-45.70%
-11.06
-25.59%
-8.81
-69.70%
-5.19
Cash Flowsfromusedin Operating Activities Direct
—
-15.94
-24.48%
-12.81
-146.68%
-5.19
Classesof Cash Payments
—
-17.29
-27.14%
-13.60
-100.76%
-6.77
Classesof Cash Receiptsfrom Operating Activities
—
1.01
+29.59%
0.78
-48.10%
1.51
Common Stock Issuance
0.00
-100.00%
8.18
-71.15%
28.33
+204.08%
9.32
Interest Received Direct
—
0.33
+5148.88%
0.01
-91.42%
0.07
Issuance Of Capital Stock
0.00
-100.00%
8.18
-71.15%
28.33
+204.08%
9.32
Other Cash Paymentsfrom Operating Activities
—
-17.29
—
—
Other Cash Receiptsfrom Operating Activities
—
1.01
+29.59%
0.78
+844.83%
0.08
Paymentson Behalfof Employees
—
—
-13.60
-51.58%
-8.97
Paymentsto Suppliersfor Goodsand Services
—
—
—
-6.77
Receiptsfrom Customers
—
0.00
0.00
-100.00%
1.51
Sale Of Business
—
—
0.00
-100.00%
0.02
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category